Now I have a thorough understanding of the paper and the calibration anchors. Let me construct the final review.

---

## Summary

MOCHA proposes a curated collection of 10 publicly available multi-sample spatially resolved transcriptomics (SRT) cohorts, each paired with expert pathologist spatial domain annotations. The paper's stated goal is to provide a resource for developing and evaluating multi-sample SRT methods. However, the manuscript is essentially a proposal — it describes the motivation and lists existing datasets, provides a generic review of preprocessing and batch correction methods, and briefly surveys three existing multi-sample methods, but contains no experiments, no empirical validation, no concrete resource description, and no access point.

## Strengths

- **Well-motivated problem**: Multi-sample SRT analysis with expert annotations is a genuine gap in the field. The paper correctly identifies that existing repositories (SODB, Aquila, SORC) lack multi-subject cohorts with expert-derived spatial domain labels (Section 1).
- **Diverse cohort selection**: The 10 cohorts span multiple tissue types (breast, colorectal, kidney, lung, renal cell carcinoma, brain, mouse olfactory bulb), technologies (10x Visium, ST), and scales (3 to 94 subjects) — a reasonable foundation for a benchmark (Table 1, Section 2).
- **Clear writing**: The paper is well-organized and readable, with the problem motivation and dataset descriptions presented coherently.

## Weaknesses

### Fatal

- **No empirical evaluation of any kind.** The paper contains zero experiments, benchmarks, downstream task results, case studies, or any demonstration that the assembled data and annotations enable reproducible method comparison. The abstract claims MOCHA supports "algorithm development and evaluation," but the paper provides no evaluation framework, no baseline results, and no evidence that the resource is fit for this purpose. For a contribution positioned as enabling evaluation, the absence of any evaluation of the contribution itself is a fundamental structural flaw that invalidates the paper's core claim.

- **The resource is not delivered or concretely described.** A resource paper must describe the resource in sufficient detail that it is clear what is being contributed and how it can be used. This paper provides: no concrete data format specification, no file structure, no access endpoint or download instructions, no code, no documentation. Section 3 is not a protocol specific to MOCHA — it is a generic review of TMM, RLE, Harmony, Crescendo, etc. that exists in dozens of published tutorials. The paper asserts that MOCHA provides "standardized data organization" and "efficient storage formats" (abstract) but substantiates neither claim.

- **The annotation process is entirely undocumented.** The paper's central differentiator is expert pathologist annotations for every sample. Yet the manuscript provides no information about: number of annotators, their qualifications, the annotation protocol, inter-annotator agreement, how disagreements were resolved, or the granularity of the labels. Section 4 defers the annotation scheme to the Supplementary Material, but even the basic methodology — how many pathologists, what protocol, what quality control — belongs in the main text of a paper whose contribution hinges on annotation quality. Without this, the annotations cannot be trusted, and the paper's main claim collapses.

### Major

- **Sections 3 and 4 are literature reviews, not contributions.** Section 3 (Pre-processing and batch effect correction) is a generic tutorial covering TMM, RLE, Harmony, Crescendo, etc. — none of which the paper implements, evaluates, or ties specifically to MOCHA. Figure 2 shows a single run of Harmony on one cohort, but no parameters, reproducibility details, or quantitative results are provided. Section 4 is a short paragraph and a 3-row table listing BayeSMART, BASS, and STAGATE, with no comparison, evaluation, or integration with the MOCHA resource. These sections read like background for a methods paper that was never written.

- **No evidence that the annotation labels are usable for evaluation.** Even setting aside the undocumented annotation process, the paper provides no label distribution statistics, no spatial visualization of annotations overlaid on H&E images, and no demonstration that the four broad categories (immune, stroma, tumor, normal) are consistently defined across cohorts. Without this, a reader cannot assess whether the labels support the claimed benchmarking use case.

### Minor

- **The paper ends abruptly** with empty Author Contributions and Acknowledgments sections and no Discussion or Limitations section. This reinforces the impression that the manuscript is an incomplete draft.

## Nice-to-Haves

- A benchmark experiment applying existing multi-sample methods (BayeSMART, BASS, STAGATE) to MOCHA cohorts and evaluating against the pathologist annotations with metrics like ARI or NMI would transform this from a proposal into a contribution.
- Spatial visualization of annotations overlaid on H&E images for each cohort would help readers qualitatively assess label quality.
- A comparison to existing resources (SODB, Aquila, SORC) demonstrating what scientific questions MOCHA enables that they cannot would strengthen the motivation.

## Removed Points

These points are flagged to be removed, treat them with caution.

- **Harsh Critic #2's claim that "the resource is not actually delivered" might partly reflect the parser stripping the Supplementary Material** — however, even accounting for this, the main text lacks the minimal description of format, structure, and access that a resource paper requires. The weakness as reformulated above ("not concretely described") remains valid and is retained.

- **Strength Finder's claim of "reproducible preprocessing workflow"** — removed because Section 3 is a generic literature review, not a reproducible pipeline specific to MOCHA. It describes what others have done, not what MOCHA provides.

- **Strength Finder's claim of "practical accessibility" with Python/R formats** — removed because the paper asserts this in the abstract but never demonstrates or specifies it. No formats, no code, no access mechanism is described. This strength exists only as an unsubstantiated claim.

- **Harsh Critic's demand to "quantify batch effects and demonstrate the need for batch correction"** — moved to nice-to-have. While it would strengthen the paper, a resource paper could reasonably assert the need for batch correction based on the well-established literature without re-proving it.

- **Harsh Critic's demand to "release the resource with a documented access point"** — this is captured in the fatal weakness about the resource not being described. It is not a "missing next step" but a fundamental missing component of the paper as submitted.

- **All formatting/typo criticisms** — removed per hard rules. These are parser artifacts.

## Novel Insights

None beyond the paper's own stated motivation. The paper identifies a real gap — multi-sample SRT cohorts with expert annotations — but does not provide any empirical or methodological insight that advances understanding beyond what the individual source papers already established.

## Suggestions

- The paper needs a complete restructuring. The minimum viable version would: (1) fully document the annotation process (annotator qualifications, protocol, inter-rater reliability), (2) specify the concrete data format, file organization, and access mechanism, (3) include at least one benchmark experiment demonstrating that the resource actually enables multi-sample method evaluation, (4) show spatial visualizations of annotations across cohorts.
- Sections 3 and 4 should either be removed (they add no novel content) or replaced with a concrete, MOCHA-specific pipeline that is actually implemented and demonstrated.
- Even a modest evaluation — e.g., running one multi-sample method on one cohort and comparing to the pathologist labels with one metric — would shift this from a proposal to a paper with evidence.

## Score and Decision

### Anchor comparison

| Anchor | Avg Score | Comparison to MOCHA |
|---|---|---|
| `wAb8vtEZfM` (Size Doesn't Matter) | 1.20 | That paper was incoherent, LLM-generated, with unsupported claims. MOCHA is better: it is coherent, well-organized, and addresses a real problem. |
| `0oxkxG9cCo` (IL3D) | 2.00 | IL3D integrated existing datasets and had experiments, benchmarks, and comparisons despite limited novelty. MOCHA is slightly worse: it also aggregates existing data but has zero experiments. |
| `7negqZWb2S` (RIoT) | 3.50 | RIoT involved real data collection effort, had use-case demonstrations (anomaly detection, HVAC optimization), actual data release, and code. MOCHA is markedly worse: no experiments, no concrete resource. |
| `WDNmAe2v6O` (GPattern-Bench) | 4.00 | GPattern-Bench had experiments, baselines, a new method, and comparative evaluation despite being a simple aggregation. MOCHA is significantly worse. |
| `QBvxXzHdZx` (ATLAS) | 6.40 | ATLAS provided a real production dataset, a full benchmark suite with prediction and scheduling tasks, multiple baselines, and released code. MOCHA is far below this standard. |
| `0wSlFpMsGb` (Common Corpus) | 7.00 | Common Corpus delivered a 2T-token dataset with detailed curation pipeline, model training results, and released tools. MOCHA does not approach this bar. |

MOCHA sits closest to IL3D (2.00) in nature — both aggregate existing public data and claim value through curation rather than new data generation. IL3D at least included experiments and comparisons. MOCHA has none. A score of 2.0 reflects that the paper is coherent and addresses a real problem, but is fundamentally incomplete — it delivers neither a functioning resource nor any empirical evidence that its claimed contribution exists.

MY FINAL SCORE: <pineapple>2.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>